Linlin Li1, Jie Qin2, Tingting Fu2, Jiaxiang Shen3. 1. Department of Ophthalmology, People's Hospital of Rizhao, No. 126 Tai'an Road, Donggang District, Rizhao, 276800, Shandong, China. 2. Department of Ophthalmology, Rizhao Central Hospital of Shandong, No. 66 Wanghai Road, Donggang District, Rizhao, 276800, Shandong, China. 3. Department of Ophthalmology, People's Hospital of Rizhao, No. 126 Tai'an Road, Donggang District, Rizhao, 276800, Shandong, China. shenjiaxiang0427@sina.cn.
Abstract
PURPOSE: Glaucoma is a common chronic neurodegenerative disease, which could lead to visual loss. In this study, we aimed to investigate whether fisetin, a natural flavone with anti-inflammatory and antioxidant properties, is able to alleviate glaucoma. METHODS: We employed a DBA/2J mouse model which was treated with or without fisetin. Pattern electroretinogram (P-ERG), visual evoked potentials (VEPs) and intraocular pressure (IOP) were evaluated. Quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) were used to measure the expression levels of TNF-α, IL-1β and IL-6. Western blotting was performed to assess the activation of nuclear factor kappa-B (NF-κB). RESULTS: We found that DBA/2J mice treated with fisetin (10-30 mg/kg) showed improved P-ERG and VEP amplitudes and reduced IOP compared to untreated DBA/2J mice. In addition, there were more survived retinal ganglion cells (RGCs) and less activated microglia in fisetin-treated DBA/2J mice than those in untreated mice. Furthermore, secreted protein levels and mRNA levels of TNF-α, IL-1β and IL-6 were significantly repressed by fisetin. The phosphorylated p65 level in the nucleus was dramatically reduced in fisetin-treated mice compared to it in untreated mice. Our results demonstrate that fisetin may exert its function through regulating cytokine productions and inhibiting NF-κB activation in the retina. CONCLUSION: In conclusion, fisetin is able to promote the visual functions of DBA/2J mice by inhibiting NF-κB activation.
PURPOSE:Glaucoma is a common chronic neurodegenerative disease, which could lead to visual loss. In this study, we aimed to investigate whether fisetin, a natural flavone with anti-inflammatory and antioxidant properties, is able to alleviate glaucoma. METHODS: We employed a DBA/2J mouse model which was treated with or without fisetin. Pattern electroretinogram (P-ERG), visual evoked potentials (VEPs) and intraocular pressure (IOP) were evaluated. Quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) were used to measure the expression levels of TNF-α, IL-1β and IL-6. Western blotting was performed to assess the activation of nuclear factor kappa-B (NF-κB). RESULTS: We found that DBA/2J mice treated with fisetin (10-30 mg/kg) showed improved P-ERG and VEP amplitudes and reduced IOP compared to untreated DBA/2J mice. In addition, there were more survived retinal ganglion cells (RGCs) and less activated microglia in fisetin-treated DBA/2J mice than those in untreated mice. Furthermore, secreted protein levels and mRNA levels of TNF-α, IL-1β and IL-6 were significantly repressed by fisetin. The phosphorylated p65 level in the nucleus was dramatically reduced in fisetin-treated mice compared to it in untreated mice. Our results demonstrate that fisetin may exert its function through regulating cytokine productions and inhibiting NF-κB activation in the retina. CONCLUSION: In conclusion, fisetin is able to promote the visual functions of DBA/2J mice by inhibiting NF-κB activation.
Authors: Fera Y Goh; Nadine Upton; Shouping Guan; Chang Cheng; Muthu K Shanmugam; Gautam Sethi; Bernard P Leung; W S Fred Wong Journal: Eur J Pharmacol Date: 2012-01-20 Impact factor: 4.432
Authors: Frédéric Lebrun-Julien; Mathieu J Bertrand; Olivier De Backer; David Stellwagen; Carlos R Morales; Adriana Di Polo; Philip A Barker Journal: Proc Natl Acad Sci U S A Date: 2010-02-03 Impact factor: 11.205
Authors: Frédéric Lebrun-Julien; Laure Duplan; Vincent Pernet; Ingrid Osswald; Przemyslaw Sapieha; Philippe Bourgeois; Kathleen Dickson; Derek Bowie; Philip A Barker; Adriana Di Polo Journal: J Neurosci Date: 2009-04-29 Impact factor: 6.167
Authors: Francisco M Nadal-Nicolás; Manuel Jiménez-López; Manuel Salinas-Navarro; Paloma Sobrado-Calvo; Juan J Alburquerque-Béjar; Manuel Vidal-Sanz; Marta Agudo-Barriuso Journal: PLoS One Date: 2012-11-16 Impact factor: 3.240
Authors: Richard T Libby; Yan Li; Olga V Savinova; Joseph Barter; Richard S Smith; Robert W Nickells; Simon W M John Journal: PLoS Genet Date: 2005-07-25 Impact factor: 5.917